Jiangsu Hengrui Pharmaceuticals stock (CNE0000014X5): Bristol Myers $15.2B deal sparks rally

Jiangsu Hengrui Pharmaceuticals announced a major global strategic collaboration with Bristol Myers Squibb, valued at up to $15.2 billion, covering 13 preclinical programs in oncology, hematology, and immunology. The deal includes $600 million upfront payments to Hengrui by 2028, with Bristol Myers gaining exclusive rights outside Greater China for four programs. Hengrui's shares jumped as much as 16% in Hong Kong and hit the 10% daily limit in Shanghai, according to GuruFocus as of May 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

Jiangsu Hengrui Pharmaceuticals: core business model

Jiangsu Hengrui Pharmaceuticals focuses on research, development, manufacturing, and sales of innovative pharmaceuticals, with a strong emphasis on oncology, anti-infectives, and surgical drugs. The company invests heavily in R&D, maintaining a pipeline of over 20 clinical-stage candidates. This model relies on in-house innovation combined with strategic global partnerships to accelerate commercialization.

Listed on the Shanghai Stock Exchange under ticker 600276.SH and in Hong Kong, Hengrui generates the majority of its revenue from the Chinese market but is expanding internationally through licensing deals. The recent Bristol Myers agreement exemplifies this approach, providing upfront cash and milestone payments while retaining regional control in Greater China, according to GuruFocus as of May 2026.

Main revenue and product drivers for Jiangsu Hengrui Pharmaceuticals

Key products include Camrelizumab (SHR-1210), an anti-PD-1 antibody approved for multiple cancers in China, and Pyrotinib for HER2-positive breast cancer. These blockbusters drive over 50% of sales. The company also markets generic injectables and surgical anesthetics, contributing steady cash flow for R&D.

Pipeline advancements, such as regulatory nods for SHR-3821 injection, adebrelimab, and relafusp for cancer trials from China's NMPA, signal growth potential, per Marketscreener as of May 2026. Partnerships like the BMS deal enhance revenue visibility through milestones up to $15.2 billion.

Industry trends and competitive position

China's pharma sector is booming with biologics and ADCs, where Hengrui ranks among top innovators by R&D spend. It competes with Innovent and BeiGene but differentiates via broad pipeline and efficient early-stage development. The BMS collaboration positions it to leverage US market access indirectly.

Why Jiangsu Hengrui Pharmaceuticals matters for US investors

US investors gain exposure to China's high-growth pharma innovation via Hengrui's ADRs or global partners like Bristol Myers (NYSE: BMY). The $15.2B deal links Hengrui's pipeline to BMY's US commercialization, offering indirect play on oncology trends amid US-China biotech ties. Hengrui's stock traded at CNY 55.86 on Shanghai as of recent data from Google Finance May 2026.

Conclusion

The Bristol Myers Squibb partnership marks a pivotal milestone for Jiangsu Hengrui Pharmaceuticals, unlocking substantial value from its preclinical assets while shares reflect market enthusiasm. Ongoing regulatory approvals and pipeline progress support long-term growth, though execution risks in clinical development remain. Investors monitoring global biotech deals will watch how this unfolds for cross-border pharma collaboration.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.